Re-Irradiation for Recurrent Glioblastoma Multiforme

Area of Science:

• Neuro-oncology
• Radiation Oncology
• Clinical Research

Background:

• Recurrent glioblastoma multiforme (GBM) presents significant treatment challenges.
• Personalized therapeutic strategies are crucial for improving patient outcomes.
• Re-irradiation is a potential option for patients with recurrent GBM.

Purpose of the Study:

• To identify predictors of survival in patients undergoing re-irradiation for recurrent GBM.
• To inform the personalization of re-irradiation treatment strategies.
• To analyze the impact of various clinical and dosimetric factors on survival.

Main Methods:

• Retrospective analysis of 28 patients with recurrent GBM.
• Evaluation of nine factors including recurrence characteristics, performance status, and radiation dose.
• Univariate and multivariate survival analyses were performed.

Main Results:

• Gross total resection (GTR), higher equivalent dose in 2-Gy fractions (EQD2) of re-irradiation (≥30 Gy), and cumulative EQD2 (≥90 Gy) were associated with improved survival.
• Multivariate analysis confirmed frontal recurrence location and cumulative EQD2 ≥90 Gy as significant predictors.
• Trends suggested better survival with KPS 80-100% and EQD2 ≥30 Gy.

Conclusions:

• Frontal location and cumulative EQD2 ≥90 Gy are significant predictors of survival after re-irradiation for recurrent GBM.
• Re-irradiation doses of EQD2 ≥30 Gy appear to offer superior outcomes compared to lower doses.
• These findings support the development of personalized re-irradiation protocols for recurrent GBM.